In the early trial, most patients achieved deep remission and remained disease-free up to three years after treatment. The approach offers hope for a previously untreatable form of blood cancer and illustrates the potential of gene-edited immunotherapies.

Credits: envato elements; Author: YuriArcursPeopleimages;

The therapy uses base-editing technology to modify donor immune cells to recognise and destroy cancerous T-cells. Scientists caution that larger clinical studies are still needed to verify long-term safety and wider applicability before the therapy can become standard practice.